Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT
Authors:
- Robert E BristowRBRobert E Bristow
- Marcela G del CarmenMCMarcela G del Carmen
- Harpreet K PannuHPHarpreet K Pannu
- Christian CohadeCCChristian Cohade
- Mariana L ZahurakMZMariana L Zahurak
- Elliot K FishmanEFElliot K Fishman
- Richard L WahlRWRichard L Wahl
- F.J MontzFMF.J Montz
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (3) , 519-528
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated LevelsJournal of Clinical Oncology, 2001
- Playing the Waiting Game … The Asymptomatic Patient with Recurrent Ovarian Cancer Detected Only by Rising Ca125 LevelsScottish Medical Journal, 2001
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Comparative Evaluation of Diagnostic Methods in Ovarian Carcinoma with Emphasis on CT and MRIGynecologic Oncology, 1994
- CT and MR Accuracy in the Detection of Tumor Recurrence in Patients Treated for Ovarian CancerJournal of Computer Assisted Tomography, 1993
- Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125Gynecologic Oncology, 1992
- Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989
- CT prior to second-look operation in ovarian cancerAmerican Journal of Roentgenology, 1988
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1986
- Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findingsJAMA, 1986